• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Stem Cell Therapy International, Inc. (SCII) Announces That It Has Received Licensing Requests From India, Australia and Indonesia for Its New Medical Breakthrough "No Scars" Stem Cell Treatment for Burn Victims

Posted on: Tuesday, 29 May 2007, 09:00 CDT

Stem Cell Therapy International, Inc. (OTCBB: SCII), a leading stem cell research company operating international treatment clinics, announced today that it has been contacted by representatives for companies in India, Australia and Indonesia regarding acquiring the technology and license rights to SCII's new "no scars" stem cell treatment for burn patients. "We have prepared and submitted drafts of our licensing proposal including our standard $1 million initial fee per country in addition to a negotiated royalty per treatment," said Calvin Cao, president and CEO of Stem Cell Therapy International. "Our proprietary, patent pending, 'no scars' stem cell treatment for burn victims is just one of several different cutting-edge stem cell treatments that SCII has developed and is now able to license to physicians and medical groups around the world. We are just getting started to expand our current treatment clinics in the Ukraine, Mexico and China to an additional 9 countries," stated Cao, who began his trip on Sunday to conduct onsite inspections with current affiliates in China and proposed new affiliates in India. Mr. Cao recently returned from an onsite inspection trip for a planned new affiliate treatment clinic in Costa Rica. The discussions with the groups from Australia and Indonesia will be continued by the company's legal counsel for licensing, Gerald R. Newman, Esq., while Mr. Cao is on his business travels.

About Stem Cell Therapy International

Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company's website www.SCTIcorp.com

Forward-Looking Statements. This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

 For more information, please contact:  Stem Cell Therapy International, Inc.  Investor Relations Mirador Consulting Inc. T: 561-989-3600   New Clinic Partners, Licensing and Joint Ventures Gerald R. Newman, Esq. T:  310-652-6642 E.  gnewman@mergerslawyer.com

SOURCE: Stem Cell Therapy International, Inc.

Source: MARKET WIRE

More News in this Category